Clinical Study of Allergic Rhinitis Therapy by Stem Cells (NCT05151133) | Clinical Trial Compass
UnknownPhase 1
Clinical Study of Allergic Rhinitis Therapy by Stem Cells
China18 participantsStarted 2022-06-13
Plain-language summary
The investigators is now carrying out a clinical study of Umbilical cord Mesenchymal Stem Cells (UCMSCs) in the treatment of Allergic rhinitis (AR). UCMSCs is known to its multilineage differentiation potential, strong proliferation ability, low immunogenicity, convenient material acquisition, and fewer restrictions on ethical and moral issues. The investigators hope to find a novel, minimally invasive, effective and simple treatment for the large number of patients with persistent moderate to severe AR.
Who can participate
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients with moderate to severe persistent allergic rhinitis who meet the diagnostic criteria for allergic rhinitis (2015 Tianjin standard);
. The results of allergen examination showed that the allergen was a single allergy of dust mite;
. After more than 2 years of antihistamine, nasal glucocorticoid and other drug treatments, the curative effect is poor, and the symptoms seriously affect the patient's life;
. Age 18-60 years old;
. The patient refused to receive allergen-specific immunotherapy;
. The patient is willing to receive stem cell therapy and sign an informed consent.
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Severity and incidence of adverse events (SIAE) on the day of treatment
. The subject is accompanied by sinusitis, asthma and aspirin intolerance;
. The subjects suffer from severe primary heart, liver, lung, kidney and blood diseases;
. The subjects suffer from Malignant tumors;
. The subjects suffer from severe immune diseases;
. The subjects suffer from mental illness;
. Female subjects who are or are about to become pregnant, pregnant or breastfeeding;
. Patients who are participating in other clinical trials;
. In addition to the above conditions, there are other reasons why researchers believe that they are not suitable to participate in this clinical study.